Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-IL-1 alpha monoclonal antibody XB2001

A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the inflammatory cytokine interleukin-1 alpha (IL1a), with potential antineoplastic, anti-cachectic and anti-angiogenic activities. Upon administration, anti-IL1a monoclonal antibody XB2001 targets, binds to, and inhibits the activity of IL1a. This may inhibit IL1a-mediated tumorigenesis, angiogenesis and cachexia. IL1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion. In addition, IL1a mediates metabolic activity, which may cause fatigue, anorexia, and anxiety.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-IL1a monoclonal antibody XB2001
Code name:XB 2001
XB-2001
XB2001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search